Ovarian Cancer Treatment in India
Get Ovarian Cancer Treatment at internationally accredited (JCI/NABH) Indian hospitals at a fraction of Western costs, with end-to-end international patient support — visa, travel, stay, and follow-up care.
Ovarian Cancer Treatment in UAE
Ovarian Cancer Treatment at leading UAE hospitals in Dubai and Abu Dhabi — world-class care closer to home, visa-free entry for many nationalities, international specialists, and modern facilities.
Overview
Ovarian cancer treatment encompasses a multimodal spectrum of interventions—including cytoreductive surgery, platinum-based chemotherapy, targeted biological agents (PARP inhibitors, bevacizumab), and HIPEC (Hyperthermic Intraperitoneal Chemotherapy)—delivering 5-year survival rates of 70–90% for early-stage disease and 30–40% for advanced stages when managed at high-volume oncology centres. GAF Healthcare connects international patients to JCI- and NABH-accredited cancer institutes in India and JCI- and DHA-licensed oncology hospitals in Dubai and Abu Dhabi, where multidisciplinary tumour boards, robotic-assisted surgery, and next-generation molecular profiling are standard of care. Patients choose GAF Healthcare for seamless end-to-end coordination—from remote tumour board review and visa facilitation to post-treatment surveillance plans—at costs that are 40–65% lower in India than comparable Western centres, with the UAE offering a premium, geographically accessible alternative for patients from the Middle East, Africa, and Europe.
Hospital Stay: 7–14 days (varies by stage: primary debulking surgery typically 7–10 days; HIPEC procedures 10–14 days; chemotherapy cycles are outpatient or short-stay) • Total Stay in Country (Fit-to-Fly): 4–8 weeks post-surgery for international flight clearance (longer end for HIPEC or interval debulking after neoadjuvant chemotherapy; chemotherapy-only patients may fly between cycles with oncologist approval) • Success Rate: 70–90% (Stage I–II); 30–45% (Stage III–IV) — 5-year overall survival at high-volume centres
What Is It?
Ovarian cancer is the most lethal gynaecological malignancy, primarily because over 70% of cases are diagnosed at FIGO Stage III or IV, when the disease has disseminated beyond the pelvis into the peritoneal cavity and, less commonly, to distant organs. The three principal histological subtypes are epithelial ovarian carcinoma (accounting for ~90% of cases, with high-grade serous carcinoma being the most common and aggressive variant), germ cell tumours (more common in younger women, with generally better prognosis), and sex cord-stromal tumours. The disease causes progressive abdominal distension, ascites, bowel dysfunction, and systemic cachexia by compressing and infiltrating pelvic and abdominal structures; BRCA1/BRCA2 germline mutations confer a lifetime risk of 40–60% and are pivotal in treatment planning.
The physiological impact of advanced ovarian cancer is profound: malignant ascites impairs respiratory mechanics and nutritional absorption, peritoneal carcinomatosis disrupts bowel motility, and platinum-based chemotherapy exerts nephrotoxic, neurotoxic, and haematological side effects that require meticulous supportive care. Pre-treatment assessment therefore requires comprehensive cardiopulmonary evaluation (ECHO, PFTs), renal function profiling, CA-125 and HE4 biomarkers, germline BRCA and somatic tumour testing, and high-resolution contrast CT or PET-CT for Peritoneal Cancer Index (PCI) scoring—an objective measure (0–39) that guides surgical resectability.
The internationally accepted standard of care follows NCCN and ESMO guidelines: primary cytoreductive surgery (debulking) aiming for R0 resection (no macroscopic residual disease), followed by adjuvant carboplatin/paclitaxel chemotherapy (typically 6 cycles), with bevacizumab added for advanced disease and PARP inhibitor maintenance (olaparib, niraparib, or rucaparib) for BRCA-mutated or HRD-positive patients. For patients presenting with unresectable disease, neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) is equally effective and reduces surgical morbidity. HIPEC at the time of surgery is increasingly incorporated at specialist centres for selected Stage III patients, offering direct intraperitoneal cytotoxicity that systemic chemotherapy cannot replicate.
Candidates
• ELIGIBLE PATIENTS:
• Women with confirmed epithelial ovarian, fallopian tube, or primary peritoneal carcinoma at any FIGO stage seeking curative or optimal cytoreductive surgery
• Patients with germ cell or sex cord-stromal ovarian tumours requiring fertility-sparing or radical surgery
• Patients with BRCA1/BRCA2 mutations or HRD-positive tumours who are candidates for PARP inhibitor maintenance therapy
• Patients with recurrent platinum-sensitive ovarian cancer eligible for secondary cytoreduction (DESKTOP III criteria: ECOG 0–1, complete resection at first surgery, no ascites)
• Patients with platinum-resistant recurrence requiring second-line chemotherapy (liposomal doxorubicin, gemcitabine, topotecan) or clinical trial enrolment
• Patients with Peritoneal Cancer Index (PCI) ≤20 who are candidates for HIPEC in combination with cytoreductive surgery
• REQUIRED PRE-TREATMENT DIAGNOSTICS:
• Contrast-enhanced CT scan of chest, abdomen, and pelvis (standard staging)
• PET-CT scan (for equivocal lesions, recurrence assessment, or preoperative roadmapping)
• Serum CA-125, HE4, and ROMA score calculation
• Germline BRCA1/BRCA2 testing (blood); somatic tumour testing for HRD, TP53 mutation status
• Transvaginal and transabdominal ultrasound
• Diagnostic laparoscopy for Peritoneal Cancer Index (PCI) assessment and tumour biopsy in suspected unresectable cases
• Full blood count, renal panel (eGFR critical for carboplatin dosing), liver function tests, coagulation profile
• Echocardiogram (ECHO) if bevacizumab is planned (hypertension/cardiac risk assessment)
• Pulmonary function tests if HIPEC is under consideration
• Gynaecological oncology and medical oncology multidisciplinary tumour board review
• CONTRAINDICATIONS / CAUTION FLAGS:
• PCI >20 with high-volume retroperitoneal or hepatic parenchymal involvement (relative contraindication to primary surgery; NACT preferred)
• Uncontrolled cardiovascular disease, severe pulmonary hypertension, or ECOG performance status ≥3 (surgery contraindicated; systemic therapy only)
• Severe renal impairment (eGFR <30 mL/min) — cisplatin/carboplatin dosing requires nephrological review
• Active, uncontrolled infection or sepsis
• Bowel obstruction requiring emergency intervention prior to oncological planning
• Significant coagulopathy not correctable prior to surgery
Procedure
SURGICAL APPROACHES:
1. Primary Cytoreductive Surgery (Upfront Debulking): The gold standard for resectable Stage III–IV ovarian cancer. Performed by a gynaecological oncologist, it includes total hysterectomy, bilateral salpingo-oophorectomy (BSO), infracolic omentectomy, pelvic and para-aortic lymphadenectomy, peritoneal stripping, and, where necessary, bowel resection with primary anastomosis, diaphragm stripping/resection, splenectomy, or cholecystectomy. The surgical goal is R0 resection — no macroscopic residual tumour — which is the single strongest predictor of survival in advanced ovarian cancer.
2. Fertility-Sparing Surgery: For Stage IA Grade 1–2 epithelial cancers or germ cell tumours in women of reproductive age: unilateral salpingo-oophorectomy with comprehensive surgical staging (peritoneal biopsies, omentectomy, lymph node sampling), preserving the contralateral ovary and uterus.
3. Robotic-Assisted Laparoscopic Surgery (da Vinci System): Available at premier oncology centres in India (Tata Memorial, Apollo, Manipal) and the UAE (Cleveland Clinic Abu Dhabi, Mediclinic City Hospital Dubai). Robotic platforms offer 3D visualisation, articulated wristed instruments (EndoWrist technology), and tremor filtration, enabling precise dissection in the pelvis and para-aortic region with reduced blood loss (<200 mL vs ~400–600 mL open), shorter hospital stay (4–6 days vs 7–10 days), and faster return to chemotherapy. Best suited for early-stage disease and interval debulking after NACT.
4. Interval Debulking Surgery (IDS) after Neoadjuvant Chemotherapy (NACT): For patients presenting with unresectable disease (PCI >20, gross upper abdominal involvement, poor performance status). Three cycles of carboplatin/paclitaxel are administered first; surgical resectability is re-evaluated by CT/PET-CT; IDS is performed with curative intent if adequate response is achieved. The CHORUS and EORTC 55971 trials validate non-inferiority of this approach to primary surgery in appropriately selected patients.
5. HIPEC (Hyperthermic Intraperitoneal Chemotherapy): An advanced intraoperative technique performed immediately after cytoreductive surgery. The abdominal cavity is perfused with heated chemotherapy solution (cisplatin 75 mg/m², 41–43°C, for 90 minutes) using the open Coliseum technique or closed perfusion system. Heat synergises with platinum cytotoxicity, achieving 4–6x higher intraperitoneal drug concentration compared to systemic delivery, while systemic absorption remains low. The landmark van Driel et al. NEJM 2018 trial demonstrated a 3.5-month improvement in median overall survival with HIPEC in Stage III ovarian cancer. Available at select high-volume centres in India.
SYSTEMIC THERAPY (Medical Oncology):
6. First-Line Chemotherapy: Carboplatin (AUC 5–6) + Paclitaxel (175 mg/m²) IV every 3 weeks for 6 cycles is the global standard. Dose-dense weekly paclitaxel (Japanese JGOG 3016 protocol) offers improved PFS in some populations. Intraperitoneal (IP) chemotherapy (cisplatin + paclitaxel) per GOG 172 trial is used at select centres for optimally debulked Stage III patients, though port-related complications limit widespread adoption.
7. Targeted Biological Therapy — Bevacizumab (Avastin): A VEGF-A monoclonal antibody added to chemotherapy in high-risk Stage III–IV or Stage IV patients (ICON7/GOG 218 trials). Administered concurrently with carboplatin/paclitaxel and continued as maintenance for 15–22 cycles. Requires blood pressure monitoring and ECHO assessment; contraindicated within 28 days of major surgery due to impaired wound healing.
8. PARP Inhibitor Maintenance Therapy: The most significant therapeutic advance in ovarian cancer in a decade. Post-chemotherapy maintenance with olaparib (Lynparza), niraparib (Zejula), or rucaparib (Rubraca) dramatically extends progression-free survival. Olaparib in BRCA-mutated patients (SOLO-1 trial) reduced risk of progression or death by 70% vs placebo; niraparib (PRIMA trial) benefits the broader HRD-positive population regardless of BRCA status. These oral agents are now standard maintenance for all eligible patients completing first-line platinum-based therapy.
9. Recurrence Management: Platinum-sensitive recurrence (relapse >6 months): re-treatment with carboplatin combinations ± bevacizumab ± PARP inhibitor. Platinum-resistant recurrence (relapse <6 months): single-agent non-platinum chemotherapy (pegylated liposomal doxorubicin, topotecan, gemcitabine, weekly paclitaxel) ± bevacizumab. Mirvetuximab soravtansine (IMGN853), an ADC (antibody-drug conjugate) targeting FRα, is now FDA-approved for platinum-resistant, FRα-high ovarian cancer — available at comprehensive cancer centres in India and UAE.
10. Radiation Therapy: Not a primary modality but used for palliative management of specific metastatic sites (bone, brain) or isolated pelvic recurrences in carefully selected cases. Stereotactic Body Radiotherapy (SBRT) may be applied for oligometastatic disease.
Cost of Ovarian Cancer Treatment: India vs. UAE
Ovarian cancer treatment costs vary significantly depending on FIGO stage, the extent of cytoreductive surgery, whether HIPEC is incorporated, the number of chemotherapy cycles, and the class of targeted agents prescribed. India offers world-class oncological expertise at 40–65% lower cost than comparable UAE centres, making it the primary destination for budget-conscious patients from South Asia, Africa, and Southeast Asia. The UAE — particularly Dubai and Abu Dhabi — provides equivalent oncological outcomes within a premium infrastructure environment, offering a compelling advantage for patients from the GCC, Europe, and East Africa who prioritise proximity, luxury facilities, and English/Arabic-language care. Both destinations include access to full PARP inhibitor and bevacizumab protocols, robotic surgery platforms, and BRCA/HRD molecular diagnostics. Cost estimates below cover primary cytoreductive surgery plus 6 cycles of standard adjuvant chemotherapy; HIPEC adds approximately $4,000–$6,000 (India) or $10,000–$15,000 (UAE), and PARP inhibitor maintenance adds $1,500–$3,000/month depending on drug availability and institutional negotiation.
| Destination | Estimated Cost (USD) | Key Advantage |
|---|---|---|
| India | $8,000 – $22,000 | ~52% less than the UAE |
| UAE (Dubai/Abu Dhabi) | $18,000 – $45,000 | Premium care, JCI/DHA accredited |
Estimates typically include surgery, hospital stay, and standard medications. Contact us for a personalised quote.
Recovery & Aftercare
PHASE 1 — REMOTE PRE-CONSULTATION (Week 1–2, from home country):
• Patient submits medical records, imaging (CT/PET-CT), pathology reports, and biomarker results to GAF Healthcare's oncology coordination team.
• Remote tumour board review conducted by gynaecological oncologist and medical oncologist at the receiving institution.
• GAF Healthcare provides a written Treatment Roadmap: proposed surgical approach, chemotherapy protocol, estimated duration of stay, and itemised cost estimate.
• e-Medical visa application initiated for India (typically 3–5 business days approval); UAE tourist/medical visa or visa-on-arrival processed per patient nationality.
PHASE 2 — ARRIVAL & PRE-OPERATIVE WORKUP (Days 1–3 in country):
• GAF Healthcare airport transfer (private vehicle, attendant welcome) to hospital-affiliated accommodation or hospital itself.
• Day 1: Outpatient oncology consultation — clinical examination, review of imaging, confirmation of surgical plan.
• Day 2: Pre-operative investigations if not already completed — repeat CT if >6 weeks old, ECHO (if bevacizumab planned), anaesthesia assessment, blood work (CBC, BMP, coagulation, CA-125 baseline), and bowel preparation protocol initiation.
• Day 3: Diagnostic laparoscopy if PCI assessment required prior to committing to open cytoreduction; anaesthesia consent; final surgical consent with gynaecological oncologist.
PHASE 3 — SURGERY (Day 4, or Day 1–2 for early-stage robotic cases):
• Primary cytoreductive surgery (open midline laparotomy): 4–8 hours under general anaesthesia. Intraoperative frozen section pathology guides extent of resection. HIPEC administered immediately post-cytoreduction if planned (additional 90 minutes).
• Robotic-assisted surgery (early-stage/IDS): 3–5 hours; patient transferred to HDU (high-dependency unit) post-operatively.
• NGT (nasogastric tube), urinary catheter, and abdominal drains placed intraoperatively; patient monitored in surgical HDU/ICU overnight.
PHASE 4 — IN-HOSPITAL RECOVERY (Days 5–14):
• Day 1–2 post-op: ICU or HDU — haemodynamic stabilisation, IV analgesia (epidural or IV PCA), DVT prophylaxis (LMWH + compression stockings), fluid balance monitoring.
• Day 2–4 post-op: Transfer to surgical ward; nasogastric tube removal when bowel sounds return; initiation of sips and liquid diet; early ambulation (physiotherapy-guided walking by Day 2).
• Day 4–6 post-op: Drain removal when output <100 mL/day; advancement to soft diet; wound assessment; pathology results reviewed (final histology, surgical staging, residual disease status).
• Day 7–10 post-op: Medical oncology consultation to discuss adjuvant chemotherapy protocol, BRCA/HRD results, and maintenance therapy plan. Discharge planning initiated.
• Day 10–14 (HIPEC patients): Extended monitoring for haematological toxicity (cytopenias), renal function (cisplatin nephrotoxicity), and nutritional status before discharge.
PHASE 5 — POST-DISCHARGE & IN-COUNTRY RECOVERY (Weeks 2–6):
• Patient stays in GAF Healthcare-arranged serviced apartment near the hospital with a designated patient coordinator available 24/7.
• Week 2–3: Wound review and suture/staple removal at outpatient clinic; CA-125 level checked.
• Week 3–4: Oncology review — fitness for first chemotherapy cycle assessed; Cycle 1 of carboplatin/paclitaxel administered (if adjuvant plan).
• Week 4–6: Second clinical review; confirmation of fitness to fly (no fever, wound fully healed, haemodynamically stable, no deep vein thrombosis, no pleural effusion on chest X-ray); compression stockings and LMWH prescribed for the flight.
• Fit-to-fly clearance: typically Week 5–6 for major open cytoreduction; Week 3–4 for robotic/minimally invasive surgery; chemotherapy-only patients may fly between cycles (after 72–96 hours post-infusion with oncologist written clearance).
PHASE 6 — ONGOING SURVEILLANCE (Back in home country):
• Cycles 2–6 of chemotherapy administered locally (GAF Healthcare provides a detailed treatment protocol letter for the patient's local oncologist).
• CA-125 monitoring every 3 months for 2 years, then every 6 months.
• CT restaging every 3–6 cycles and at completion of chemotherapy.
• PARP inhibitor maintenance prescription and monitoring plan provided in written discharge summary.
• Telemedicine follow-up with the treating gynaecological oncologist via GAF Healthcare's platform at 3, 6, and 12 months.
Risks & Considerations
Ovarian cancer treatment carries a spectrum of surgical and oncological risks that patients must discuss candidly with their treating team. Cytoreductive surgery — particularly when extended to include bowel resection, diaphragm stripping, or splenectomy — carries risks of intraoperative haemorrhage (transfusion rates 20–40% in radical procedures), anastomotic leak (2–5% for bowel resections), ileus (15–20%), wound infection or dehiscence (5–10%), and thromboembolic events (DVT/PE, 5–15% without prophylaxis). HIPEC adds systemic absorption of intraperitoneal cisplatin, causing nephrotoxicity (requires aggressive IV hydration and renal function monitoring), haematological toxicity (Grade 3–4 neutropenia in 30–40%), and prolonged ileus. Bevacizumab is associated with hypertension (20–30%), proteinuria, impaired wound healing (contraindicated for 28 days post-surgery), and rare but serious gastrointestinal perforation (1–3% in previously irradiated or bowel-involved disease). PARP inhibitors cause anaemia, thrombocytopenia, nausea, and fatigue in the majority of patients; rare cases of treatment-related MDS/AML have been reported with prolonged use (cumulative risk ~1%). Long-term consequences of radical surgery include surgical menopause (in premenopausal women undergoing BSO), lymphoedema (following extensive lymphadenectomy), bowel dysfunction, and peripheral neuropathy from paclitaxel (affecting 30–40% of patients, partially reversible). Disease recurrence remains the central clinical challenge: despite optimal treatment, approximately 70% of Stage III–IV patients relapse within 18–24 months of completing first-line therapy. Open communication with the GAF Healthcare-assigned multidisciplinary team about performance status, comorbidities, and patient priorities is essential to calibrate the risk-benefit profile for each individual.
Top Hospitals for Ovarian Cancer Treatment
The following JCI and NABH-accredited hospitals are among the most experienced in specialist care, with dedicated teams and high-volume programmes.
Apollo Hospitals
New Delhi, India
Medanta - The Medicity
Gurgaon, India
Kokilaben Dhirubhai Ambani Hospital
Mumbai, India
Tata Memorial Hospital
Mumbai, India
Top Doctors for Ovarian Cancer Treatment
Internationally trained specialists in Cancer Care. Review their profiles, compare experience, and connect directly through GAF Healthcare.
Dr. Vinod Raina
MBBS, MD (Internal Medicine), DM (Medical Oncology), Fellowship, Fellowship
Medical Oncologist
Fortis Memorial Research Institute, Gurgaon, India
40+ Yearsof experience
Dr. Vinod Raina is a distinguished figure in the field of Medical Oncology in India, with over 40 years of exemplary experience. He is currently associated with Fortis Memorial Research Institute in Gurugram, where he functions as the Chairman and Head of Medical Oncology and Hematology. His primary expertise lies in chemotherapy treatment and he was the first to perform high-dose chemotherapy in India. He also performed the first peripheral blood BMT in… Read more
Dr. Kanchan Kaur
MBBS, MS (General Surgery), MRCS
Surgical Oncologist (Breast)
Medanta - The Medicity, Gurgaon, India
22+ Yearsof experience
Dr. Kanchan Kaur is a senior breast cancer and general surgeon who serves as Senior Director — Breast Cancer at the Cancer Care division of Medanta – The Medicity, Gurgaon. With more than two decades of surgical experience, she has built a multidisciplinary breast practice that combines oncologic clarity with deep patient empathy. Dr. Kanchan is widely respected for her work in breast cancer awareness and early detection. She works closely with several… Read more
Dr. Ashwin Sunil Tamhankar
MBBS, MS, MCh Urology, DNB Urology, Vattikuti Robotic Uro-oncology Fellowship, RCS Laser Urological Robotic Fellowship, Olympus Laparoscopic Endo-Urology Fellowship
Surgical Oncologist & Robotic Uro-Oncologist
Apollo Hospitals, Navi Mumbai, Mumbai, India
9+ Yearsof experience
Dr. Ashwin Sunil Tamhankar is a Consultant in Surgical Oncology and Robotic Surgery based at Apollo Hospitals in Navi Mumbai, India. With over 9 years of specialized experience, he has established himself as a leading uro-oncologist, combining advanced robotic surgical techniques with precision cancer care. His credentials include MBBS, MS, MCh Urology, DNB Urology, and prestigious fellowships from the Vattikuti Institute, Royal College of Surgeons of… Read more
Dr. Asit Arora
MBBS, MS, MCh
GI & HPB Surgical Oncologist
Indraprastha Apollo Hospital, New Delhi, India
22+ Yearsof experience
Dr. Asit Arora is a Clinical Lead in GI and HPB Surgical Oncology at Indraprastha Apollo Hospital, New Delhi, bringing over 22 years of specialized expertise in managing complex gastrointestinal and hepatobiliary cancers. He holds an MBBS, MS in General Surgery, and an MCh in Gastrointestinal Surgery, and is widely recognized across India and internationally for his precision in radical oncologic resections and advanced abdominal cancer surgery. Dr. Arora… Read more
Dr. B. Niranjan Naik
MBBS, MS, Onco-Surgery, FIAGES
Surgical Oncologist
Paras Hospitals, Gurugram, India
22+ Yearsof experience
Dr. B. Niranjan Naik is Principal Director of Surgical Oncology and Director of Breast & Gastro-Intestinal Onco-Surgery at Paras Hospitals in Gurugram. With over 22 years of distinguished clinical experience, he is widely recognized as one of the leading breast cancer surgeons in the Delhi and Gurugram region. His credentials include MBBS and MS (General Surgery) from the All India Institute of Medical Sciences (AIIMS), New Delhi, followed by specialized… Read more
Frequently Asked Questions — Ovarian Cancer Treatment
The total cost of ovarian cancer treatment — covering primary cytoreductive surgery, 6–8 days of hospitalisation, standard medications, and 6 cycles of adjuvant carboplatin/paclitaxel chemotherapy — ranges from approximately $8,000 to $22,000 USD in India, depending on the stage of disease, extent of surgery (standard debulking vs. HIPEC), and the specific institution. In the UAE (Dubai or Abu Dhabi), equivalent treatment ranges from $18,000 to $45,000 USD, reflecting the higher infrastructure and operational costs of GCC healthcare. HIPEC (Hyperthermic Intraperitoneal Chemotherapy), when indicated, adds roughly $4,000–$6,000 in India and $10,000–$15,000 in the UAE. PARP inhibitor maintenance therapy (olaparib, niraparib) — prescribed for BRCA-mutated or HRD-positive patients after completing chemotherapy — costs an additional $1,500–$3,000 per month and is not typically included in surgical package pricing. India therefore offers savings of 40–65% compared to the UAE, while both destinations offer JCI-accredited centres, robotic surgery platforms, and molecular diagnostic services. GAF Healthcare provides a personalised, itemised cost estimate based on the patient's specific staging workup before any commitment is made.
The minimum safe in-country stay before international flight clearance depends primarily on the treatment modality. For patients undergoing open primary cytoreductive surgery (the most common approach for advanced-stage disease), the fit-to-fly milestone is typically 5–6 weeks post-surgery. This accounts for full wound healing, return of bowel function, haemodynamic stability, resolution of any post-operative complications (pleural effusion, anaemia), and the administration of the first cycle of adjuvant chemotherapy — which oncologists prefer to complete locally to monitor for initial toxicity. Patients who undergo robotic-assisted minimally invasive surgery (typically for early-stage or interval debulking) can generally achieve fit-to-fly status in 3–4 weeks. Patients receiving chemotherapy only (without surgery, e.g. neoadjuvant NACT prior to interval surgery, or palliative-intent treatment) may fly home between cycles — approximately 72–96 hours after infusion — with written clearance from their oncologist, as long as blood counts are adequate. HIPEC patients require an extended stay of 6–8 weeks due to the additional haematological and renal monitoring required. All patients flying after major abdominal surgery are provided with a written fit-to-fly letter, deep vein thrombosis prophylaxis (compression stockings and low-molecular-weight heparin for 10–14 days), and a comprehensive clinical handover package for their home-country oncologist. GAF Healthcare confirms fit-to-fly clearance formally before booking the patient's return flight.
Success rates for ovarian cancer are measured by 5-year overall survival and are directly determined by FIGO stage at diagnosis and the quality of initial surgical cytoreduction — specifically whether R0 resection (no macroscopic residual tumour) is achieved. At GAF Healthcare's partner institutions — including Tata Memorial Hospital (Mumbai), Apollo Cancer Centres, Manipal Hospitals (India) and Cleveland Clinic Abu Dhabi, Mediclinic City Hospital, and American Hospital Dubai (UAE) — published and institutional outcomes are as follows: Stage I: 85–93% 5-year survival; Stage II: 70–80%; Stage III with R0 resection: 40–50%; Stage III with residual disease >1 cm: 20–30%; Stage IV: 20–30% with optimal cytoreduction and bevacizumab/PARP inhibitor maintenance. The incorporation of PARP inhibitor maintenance (olaparib) in BRCA-mutated patients has dramatically improved progression-free survival — the SOLO-1 trial demonstrated that at 5 years, 48% of BRCA-mutated patients on olaparib maintenance had not experienced disease progression versus only 21% on placebo. Chemotherapy response rates to first-line carboplatin/paclitaxel reach 70–80% (objective response), though platinum resistance develops in the majority of advanced-stage patients within 2 years. It is important to understand that success in ovarian cancer management is increasingly defined not by cure alone, but by sustained quality of life, prolonged progression-free survival, and the ability to sequence effective therapies at recurrence — an approach that requires the level of multidisciplinary expertise and molecular diagnostics available at GAF Healthcare's partner centres.
Why Plan Your Treatment Through Gaf Healthcare?
GAF Healthcare provides comprehensive non-medical coordination so that patients and their families can focus entirely on treatment and recovery.
VISA & ENTRY DOCUMENTATION:
• India: GAF Healthcare's visa team prepares and submits the e-Medical Visa application (evisa.gov.in) on the patient's behalf, including the hospital invitation letter required from the treating institution. Approval is typically granted within 3–5 business days and allows a 60-day stay, extendable. A companion e-Medical Attendant Visa is simultaneously arranged for one accompanying family member.
• UAE (Dubai / Abu Dhabi): Citizens of over 50 countries receive visa-free or visa-on-arrival access to the UAE. For nationalities requiring a pre-arranged visa, GAF Healthcare coordinates a Medical Treatment Visa through the relevant emirate authority (DHA in Dubai; DOH in Abu Dhabi), supported by a hospital appointment letter and medical summary.
AIRPORT & IN-COUNTRY TRANSFERS:
• Private, air-conditioned vehicle transfers on arrival and departure, with a GAF Healthcare patient coordinator present at the airport.
• All transfers between accommodation and hospital for appointments, surgery, chemotherapy infusions, and follow-up visits are included in the coordination package.
• Wheelchair-assisted transport and ambulance transfers arranged for patients with significant mobility limitations or post-operative status.
MEDICAL INTERPRETATION & TRANSLATION:
• Dedicated medical interpreters available in Arabic, French, Russian, Swahili, Amharic, and other languages for all clinical consultations, consent procedures, and nursing interactions.
• All discharge summaries, pathology reports, chemotherapy protocols, and follow-up instructions translated into the patient's preferred language.
ACCOMMODATION FOR PATIENT & ATTENDANT:
• GAF Healthcare partners with serviced apartments and patient-friendly guesthouses within 2 km of the treating hospital in all destination cities (Mumbai, Delhi, Chennai, Hyderabad, Dubai, Abu Dhabi).
• Options range from budget-comfortable to premium, with in-room cooking facilities (important for dietary needs during chemotherapy), reliable Wi-Fi, and 24/7 on-call support from the GAF care team.
• For patients requiring extended stays (6–8 weeks for surgery plus initial chemotherapy cycles), negotiated monthly rates are available.
CONTINUITY OF CARE:
• A detailed clinical handover package — including surgical operative notes, histopathology reports, chemotherapy protocol, BRCA/HRD test results, and the surveillance plan — is prepared for the patient's home-country oncologist.
• Telemedicine follow-up sessions with the treating specialist are facilitated by GAF Healthcare at 3, 6, and 12 months post-treatment.
• Emergency medical helpline available 24/7 throughout the patient's in-country stay.
Patients Also Explore
Other treatments commonly sought by patients considering Ovarian Cancer Treatment.
Cryosurgery
Surgical Oncology
Robotic Surgery
Surgical Oncology
Anemia
Hematology
Leukemia Treatment
Hematology